Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In case you all forgot.. in La Mesa:
Could a vaccine to fight breast cancer be developed in La Mesa?
At the very least La Mesa company Regen BioPharma could play a role, reports the San Diego Daily Transcript. Regen's logo includes the words “fast forwarding stem-cell medicine.”
Regen, a subsidiary of Bio-Matrix Scientific Group (OTC: BMSN), has a licensing agreement with Benitec Biopharma (ASX: BLT) for vaccines that can be developed using gene technology shaped by Benitec.
Ever worked in a laboratory? Help us decipher the technology they'll be using, according to the report: “the application of ddRNAi to silence indoleamine 2,3 - dioxygenase (IDO) in dendritic cells.”
Huh? Let's break it down a bit. IDO may cause immune suppression and is present when there is cancer. In preliminary work, Regan has shown that altering the cells with ddRNAi could make it more likely for use in the development of a vaccine to fight cancer.
According to a news release, Dr. David Koos, Regen's CEO, said, the work could lead to “an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
The science behind the research has been examined in The Journal of Cancer.
That's funny. Even for something you say. Or would that be especially for something that you say?
I dunno...drowning in science here.
I iggied you. How is it that your daft messages show up?
True dat, wise one!
And I will tell you what is next: application for silencing cancer genes. Oh, but they are not stopping there. No, with the latest Benetic deal, not only are looking to silence cancer genes but they are looking to teach the immune system how to successfully fight off those that escape into the body.
Hello......can we say much BANK for this little engine that could??????????????????????
First TEN Pages of Dr. Ichim's Resume (you know, the CSO of Regen. Please NOTE the Benitec connection below):
Thomas E Ichim
9255 Towne Centre Drive, #450, San Diego, CA 92121
Mobile: (858) 349 - 3617
Email: thomas.ichim@gmail.com
Place of Birth: Kitchener, Ontario, Canada
PROFESSIONAL EXPERIENCE:
2012-Present President and Chief Scientific Officer
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2008-2012 Chief Executive Officer and Chief Scientific Officer
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2007-2008 Chief of Scientific Development
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2006-2009 Chief Technology Officer
OncoMune LLC
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2004-2007 Co-Founder and Program Manager
bioRASI LLC
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2004-Present Managing Partner
Vendevia Group
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2003-2004 Scientist
Department of Surgery, University of Western Ontario
1151 Richmond Street, London, ON N6A 3K7, Canada
2003-2005 Cofounder and CEO
MedVax Pharma Corp
126 Madison Ave South, Kitchener, Ontario, Canada
2002-Present Co-founder and Vice President of Business Development
ToleroTech Inc
84 Hesketh Street, London, Ontario, Canada2000-2003 Director of Regulatory Affairs
MarrowTech Pharma Inc
26 Carriage Hill Cres, London, Ontario, Canada
1999-2000 Research Assistant
Department of Microbiology and Immunology, University of
Western Ontario, 1151 Richmond Street, London, Ontario. Canada
1995-1997 President
Batu Centre for Leukemia Research
126 Madison Ave South, Kitchener, Ontario, Canada
1993-1994 Summer Student
University of Guelph, Guelph Ontario
MAJOR ACCOMPLISHMENTS/RESPONSIBILITIES:
At Medistem:
Discovered a new stem cell that is economical to manufacture and is non-embryonic
Obtained FDA approval for testing stem cell in patients (clinical trials)
Recruited internationally-renowned doctors (Mike Murphy Indiana University, first to
use stem cells for leg conditions in USA and Amit Patel University of Utah, first to use
stem cells in human heart in world) to perform the trials
Inventing 20 families of patents and patent applications in area of regenerative medicine
Recruiting former CEO of Juvenile Diabetes Research Foundation, Alan Lewis, to
become Medistem CEO
[b]Initiated and led collaborations with biotechnology companies (Benitec Biopharma,
Aethlon Medical, Entest Biomedical, Orcrist Bio) leading to scientific publications and
Federal SBIR grant
Initiated and led collaborations with international universities including: University of
Utah; University of California San Diego; Indiana University; National Institutes of
Health; Central South University, Changsha, China; Regenerative Medicine and Cell
Therapies Laboratory, CUCAIBA, Ministry of Health Argentina; University of Western
Ontario; University of Alberta; Institute for Molecular Medicine; Karelian Research
Center, Russian Academy of Sciences, Petrozavodsk, Russia;? Recruited Medistem’s Advisory Board including Dr. Hugh Taylor, Director of
Reproductive Biology at Yale University, and Dr Gene Ray, founder and CEO of Titan
which had a 2.6 Billion liquity event
? Published 67 peer reviewed scientific publications with Medistem
At Regen BioPharma:
? Assembled clinical development program with FDA application in preparation for
treatment of aplastic anemia
? Invented 2 patents for treatment of bone marrow disorders
? One peer reviewed manuscript accepted for publication
At OncoMune:
? Obtained issued patent # 8,263,571 covering means of treating cancer by blocking new
cancer-causing gene
Developed preclinical and clinical strategy, including 1 peer reviewed publication
At bioRASI:
Designed and executed clinical trials for assessing efficacy of novel interventions in
human subjects with specialization in stem cells/regenerative medicine
Assisted clients in publishing and patenting data
At Vendevia:
Performed scientific due diligence before investment/partnerships
Designed scientific/clinical development plan for portfolio companies
Worked with the Chief Scientific Officer to develop overall technology strategy for the
fund
At Dept Surgery, University of Western Ontario (Weiping Min Lab):
Laboratory research involving cell therapy and transplantation
Filed patents on first use of RNA interference for immune modulation
Published scientific papers and assisted in grant writing
At MedVax Pharma Corp:
Invented new cancer vaccine and filed patent application
Published peer-reviewed proof of concept manuscriptAt ToleroTech:
Invented new uses of RNA interference for organ transplant rejection
Demonstrated proof-of-concept in animal models and published in peer reviewed journals
Obtained Proof of Principle grant for Wei-Ping Min’s laboratory
At Marrowtech Pharma:
Compiled preclinical data and filed successful application to perform clinical trials using
stem cell generated cancer inhibitor
At Department of Microbiology and Immunology, University of Western Ontario:
Performed laboratory experiments using stem cell generated cancer inhibitor
At Batu Center for Leukemia Research:
Developed proposal for new stem cell based method of treating leukemia in collaboration
with Dr. Mark Minden
Organized and executed national fundraising campaign to fund leukemia research
At University of Guelph
Designed and executed research project assessing effects of antioxidants on porcine
lymphocyte proliferation
Presented results at the 4
th International Veterinary Immunology Symposium, Davis
CaliforniaEDUCATION:
1990 Canadian Securities Institute, Toronto, Canada
Canadian Options and Derivatives License
1998 University of Waterloo, Waterloo, Ontario, Canada
BSc in Biology
2003 University of Western Ontario, London, Ontario, Canada
MSc Microbiology and Immunology
2005 Society of Clinical Research Associates, Chalfont, PA
Certified Clinical Research Associate
2007 University of Sciences Arts and Technology, Olveston Monserrat
Ph.D Immunology
SCIENTIFIC ADVISORY BOARDS:
MyoStim Pacers, San Diego (2011-present)
Cromos Pharmaceuticals, Moscow (2010-present)
Orcrist Inc, Edmonton, Canada, Chairman (2008-2010)
Entest Bio, La Mesa, California (2010-2011)
BOARDS:
Creative Medical, Phoenix Arizona (2011-present)
Carbon Manna (2010-2011)
Riordan Clinic, Wichita, Kansas (2009-present)
Medistem Inc (2008-present)
SOCIETIES:
American Society for Transplantation (2002-2003)
Canadian Society for Immunology (2001-2003)
Biocom (2007)
PEER REVIEW AND JOURNAL ASSOCIATIONS:
Editor StemCellPatents.com (2007-2009)
Monitoring Editor for Journal of Translational Medicine (2009-present)
Editorial Board of Pharmaceutical Patent Analysis (2011-present)
Reviewer for:Cellular Immunology,
Journal of Translational Medicine,
Expert Opinion on Biological Therapy
Current Opinion on Molecular Therapeutics
HONORS AND AWARDS
2010 NIH Grant 1R43HL096213-01A1 Woods (PI), Ichim Co-PI $125,000
Therapeutic Angiogenesis by Universal Donor Endometrial Regenerative Cells
2008 Biomed Central Publication of the Year Award for 2007. ERC discovery paper
chosen as top publication out of 200 journals.
2004 International Congress of Immunology, Travel Award
2003 American Society for Transplantation, Young Investigator Award
2001 Maclean’s Magazine Honor Roll (National Merit Award for Top Ten Canadians;
awarded for fundraising and scientific contributions to cancer research in Canada)
2001 University of Western Ontario, Department of Microbiology and Immunology, Special
University Scholarship
2001 University of Western Ontario, Department of Microbiology and Immunology Graduate
Student Travel Award
2000 Canadian Society of Immunology Travel Award
1994 Gold medal awarded at Canada Wide Science Fair.
1994 4th Place at International Science and Engineering Fair.
1994 Ontario Scholar
BOOKS AND BOOK CHAPTERS
BOOK: Wei-Ping Min, Thomas Ichim. RNA Interference: From Biology to Clinical
Applications, Humana Press, 2010 - 450 pages
BOOK: Thomas Ichim, Christine Ichim. Immunological Control of Neoplasia. Rapoport
Publishing, Ontario Canada, 1998 – 112 pages
Amit N Patel, Ramasamy Sakthivel, Thomas E Ichim, Stem Cell Therapy for Heart Failure
Using Cord Blood. Chapter 23 in Regenerative Medicine Using Pregnancy-Specific BiologicalSubstances edited by Niranjan Bhattacharya and Phillip Stubblefield, Springer Press, 2011 – 453
pages
Neil H. Riordan, Thomas E. Ichim, Famela Ramos, Samantha Halligan, Rosalia De Necochea
Campion, Gzegorz W. Basak, Steven F. Josephs, Boris R. Minev, and Ewa Carrier. Tumor Stem
Cells: Therapeutic Implications of a Paradigm Shift in Multiple Myeloma. Chapter 20 in Cancer
Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting
Measures. Springer Press, 2011, 509
PUBLISHED ABSTRACTS
D Lian, M Li, TE Ichim, B Garcia, R Zhong, and Min W-P*. Induction of “infectious tolerance”
by dendritic cells derived from tolerant allo-cardiac transplant recipients. American J
Transplantation 2004, Supplement 8, Vol 4: 394.
M Li, D Lian, TE Ichim, R Zhong, and Min W-P*. In vivo immune modulation by in vitrogenerated tolerogenic dendritic cells in murine heart transplantation. American J Transplantation
2004, Supplement 8, Vol 4: 600.
Min W-P, D Lian, M Li, TE Ichim, B Garcia, and R Zhong. Synergistic infectious tolerance by
adoptive transfer of tolerogenic dendritic cells and regularity T cells. American J
Transplantation 2004, Supplement 8, Vol 4: 412.
Min W-P, TE Ichim, KP Kusznieruk, Li M, X Huang, X Yan and R Zhong. Modulation of
dendritic cell-mediated immune responses by RNA interference. The FASEB Journal 2003. 17
(7): C267.
TE Ichim, Li M, D Zhou, X Huang, X Yan, R Zhong and Min W-P*. Generation of tolerogenic
dendritic cells by inhibiting IKK activity. The FASEB Journal 2003. 17 (7): C313.
Li M, D Lian, D Zhou, H Wang, TE Ichim, X Huang, X Yan, R Zhong and Min W-P*. In vitro
generated suppressor dendritic cells and T regulatory cells prevent allograft rejection. The
FASEB Journal 2003. 17 (7): C114.
Hill JA., DP White, TE Ichim, KP Kusznieruk, X Xia, J Yang, R Zhong, E Cairns, DA Bell and
Min W-P. Novel mechanism of immune modulation through the use of small interfering RNA.
Arthritis Rheumat 2002. 46 (9):S563.
Min W-P, D Zhou, X Xia, TE. Ichim, X Zhang, J Yang, X Huang, B Garcia, P Dutartre, AM
Jevnikar, GH Strejan , R Zhong. The role of tolerogenic dendritic dells on regulatory T cells and
transplant tolerance. Transplantation 2002. 74 (4): 133.
Min W-P. T.E. Ichim, D. Zhou, N.Kanai, D. Lian,.B. Garcia, P. Dutartre, A.M. Jevnikar, G.H.
Strejan,B.Singh. Zhong, R. LF15-0195 and anti-CD45RB antibody induce tolerance through
dendritic cells with suppressive phenotype. The FASEB Journal 2002. 16 (5): A1034.
And let us not forget that at least one deep pocket has a little reminder to visit back often to increase their position:
Private Asset Management, Inc. 750 million USD managed for 700 clients worldwide.
http://www.pamgmt.com
PAM BMSN Position as of 30 June 2013
Private Asset Management Inc 12,500 06-30-13
Gotta love BMSN! :)
Subpennies are shorted every day. BMSN is shorted every day.
I am waiting on a call back from someone to confirm if for sure Fidelity is still allowing. I was told they are but I can't swear to it.
Timothy Sykes is a well know shorter who touts Fidelity & IB when shorting penny's.
I was just told yesterday that BMSN is still being shorted by both.
BMSN
Interactive Brokers & Fidelity are two.
And yes, Fidelity does allow.
Oh no, I am adding. I am giving none up. :)
Will you shed some light on what you are accusing to be a scam?
---The company is as transparent as it gets
---You can confirm patent processes & purchasing online via the US govt site
---There are a vast number of publications on the sciences the company is harnassing
---The accolades for the doctors within the company are numerous
---The CEO has put nearly 2 million of his own money purchasing stock at much higher pps than it has been in quite some time
---They have just completed an agreement with a well known and connected company
---They have submitted the first of many IND applications with the FDA
ETC, ETC, ETC,
PLEASE, DEFINE FOR US THE SCAM!
BMSN
Sorry, just realized I answered that privately. 0031, above the ask. Still not filled.
BMSN
I have a buy order in that has been sitting all morning. Hasn't budged.
Contacting the SEC will only create more headaches and perhaps cause delays in the current processes the company is trying to complete.
They will not intervene; there is no legal justification for it. And if they were to entertain pursuing something against the company (only to later find FOR the company) the money that will be required to pay for legal counsel will be money that can be used toward seeing the treatments come to fruition.
Now, do we really want to create more issue with the state of the PPS by attempting to have the SEC scrutinize BMSN? I think not.
If you are opposed to the increase to pay for the science and all the fees associated with BMSN securing the rights, how do you propose the company pays for it? Please, spell it out for us with specifics.
BMSN
As always, great post!
BMSN
I am working on a set of pictures to post so that those who cannot see what is happening to the stock can view a couple of pictures of the activity.
A number of people have said in one way or another that they had just bought a large number of shares at the ask and then no sooner than they refresh the stock drops and they are in red.
I really don't get the passion with this stock though. There are plenty of bogus companies out there that are setup just for this type of crap. Why not go join those gangs?
PS: I haven't called the T/A yet to confirm the O/S. But, am sure what he said is true. If someone else has already noted that this is correct, sorry. I am not keeping up with the posts right now.
BMSN!
I couldn't agree more. There seems to be a taboo attached to being honest and wanting others to benefit, too.
Forewarned is forearmed. We know full well now what is happening to our investment in BMSN insomuch we know what the company is doing and where they are headed AND what manipulation is taking place.
Be proactive.
BMSN
Well, as of yesterday, at 1:00 EST, according to Marilyn, the O/S had not changed.
If you say it has changed, I have no doubt that it has. But, you know I'll call.
Have a wonderful day, Jack.
Remembering that the shorting and manipulation of this stock is the reason it has had such difficulty getting out of the slump it is in. It is their business to make money in a stock by any means. They will go to great lengths to do it. And do not care what destruction they cause in the process.
It is always wise to conduct your own dd. It is, after all, your money. There is a very large amount of verifiable dd on this site. Utilize it and make the most of it.
Regen have kept up with their timeline and continue to make advances that will, when the time is right, create so many, many benefits for a great number of people.
BMSN
Actually, O/S is still as it was before--a tick under 2B. The A/S, which was actually confirmed by the company in their filings and release last week was raised to assist with paying for Min science, incrementally.
I hardly think paying for a ground-breaking cancer combating treatment is "dumping shares".
To paraphrase something Dr. Koos said today:
The fall is going to bring out better investors as this summer winds down.
The IND application for the MIN science is close at hand. Do not ask the exact time for we are not so daft that we would dare try to squeeze this out of the company. But it is very close.
Hema...waiting on the FDA (please see my number of posts regarding the FDA and the time it takes. I do have a little bit of experience in the world of pharma. Just a weeeeeeeeee bit) Everything the FDA requested has been provided. No ifs, ands or buts about it.
If you consider the second line of this post and couple it with the fact that BMSN have been true to their timeline AND the significant amount of dd already provided, you should be able to deduce the unfolding of all of the monumental events that are occurring. But do not expect these things to happen over night--this is not child's play--this successfully introducing a revolutionary way of thinking about how to efficiently treat diseases that have plagued us for as long as we can remember.
Too, this is being done by a company that is minimizing the number of people or entities that they are beholden to so that shareholder interest is secured. For anyone that has ever operated their own business, you know this is no easy task.
As I and several others have pointed out, this company is still going strong in the face of incredible adversity; they have kept to their timeline, they have faced the FDA head on (no easy task I tell you), they have secured an agreement with a company that has strong ties to BP, they brought us up-to-date with the current financial status of pending affairs and have done so with a constant barrage of baseless & inflammatory accusations and a PPS that is manipulated as though it belongs to a company promising to harvest King Crabs from the freshwater pond in my back yard. To do this requires fortitude, commitment, ingenuity and a whole lotta teamwork.
I want you all to remember that we are not the only ones eyeing BMSN. If you care to dig enough and piss enough people off with your refusal to shut up, you, TOO, can confirm this. When these folks jump in, Lawd is my life going to be so much easier!
I am delighted that I will have the opportunity to meet with Dr. Koos & Dr. Ichim with Inventor near the end of the month. At which time I will revert with as much information as the law allows.
AND I will change my profile pic to show me cuddling Koos! (Tee, hee). :-p
PS: I have iggied a lot of people the past two days based on the sound advise received from a very wise and knowledgeable fellow investor that caused a light bulb to go off for me on Saturday morning I believe it was. I do know they are talking...I just have no idea what they are saying.
Almost forgot, if you leave a detailed message and not spew diatribes at Dr. Koos, he will return your call. Might take a wee while as he gets MANY from iHub members. But, if you are respectful and provide a legitimate query, he will call you back. Don't expect him to entertain the BS, though.
I am tired. Very tired. So, goodnight most. And to most a good night.
LONG & STRONGER THAN EVER, BMSN!
:) Thank you, Inventor.
I cannot respond to personal PM's or other sources of messages right now. I will be back here in a short while.
But, yes, absolutely what Inventor says is true. Just as all I have been saying is true.
I am very much looking forward to meeting with Dr. Koos & Dr. Ichim (David & Tom) with Inventor near the end of the month.
And yes, I will provide pictures as proof!!!
Long and about to get stronger, BMSN!
@@ CJ---My pleasure! :)
Conference call coming up. I will revert later with some pertinent DD I do hope.
Thanks for the help today. :)
BMSN!
Private Asset Management, Inc. They bought 12,500 shares of BMSN on 30 June. A small amount yet. But means very deep pockets are definitely monitoring where they are and what is going on.
PAM
BMSN
Yup. I felt the warm and fuzzy's when I discovered it.
BMSN
Any what a cause for celebration that will be. In more ways than one!
GO BMSN!
I know! I have just started looking at the L2's again for the first time since this morning very briefly. I think if more people were able to view how it is the flippers are able to keep sending this stock into the red by way of whacking it so hard and with such small amounts, they would have a much, much greater understand of the games being played. It is ridiculous.
BMSN
@@@ED--don't know what you're looking at, but Koos put over 1 1/2 million in the company by way of share purchase in 2010 alone.
1,255,081.79 to be exact. Spent where the pps fluctuated between 0.04 & 0.10. With his largest single buy being @ 0.10 pps!!!!!
So, your question/comment is???
There is in our future, a major change to the way Cancer, in all its forms, will be approached and treated. The monetary potential is out of this world. Those who spend their days researching how to make other peoples money make THEM money, know that this little company is on to something HUGE!
BMSN
When I discovered that Private Asset Management, Inc. bought into BMSN on 30 June, I was a little perplexed by the size of the purchase. On June 30, 2013, this management asset firm that manages over 750 Million USD for over 700 clients, bought 12,500 shares of BMSN. When I first mentioned this I noted that I thought maybe the purchase represents a string around the finger due to the small size.
After some phone calls and email, researching how PAM buys and who they for, I have confirmed that the purchase very much indeed is probably a string around the finger.
BMSN are being eyed by folks with very deep pockets. The day is nearing when we long and dedicated shareholders will finally see a beautiful return on our investment and our due diligence.
Private Asset Management, Inc. Check them Out!
BMSN!
Yay! Yes, team work!!!
:) Thank you, much.
BMSN
It makes you wonder why anyone would be willing to halter such a promising return for the purpose of saving a few pennies now. Why would anyone sit on the sidelines with 0.0029 when the potential is so obvious?
My pleasure. :)
BMSN!
As I have stated a number of times (and anyone is welcome to call the company in an attempt to refute my claim), when I spoke with Dr. Ichim on 17 July he indicated me that they had supplied the FDA with requested data. I did not ask for specifics. However, if you look at the PR's discussing the data and that it took a minimum of 14 days to generate, it was submitted (or at least en route for submission) right around that time.
There are more than 100 types of known cancers. In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.
In this current environment, the successful players of the future will be those that can anticipate evolution and design the most relevant clinical trials (Regen are certainly doing that). In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.
With a heightened awareness created by many renowned cancer specialists in the world, governments are being forced to take a much closer look at the manipulation perpetuated by pharmaceutical companies in their efforts to continue to profit ungodly amounts at the risk of patients. Many are accused of profiteering by way of the astronomical prices for cancer treatments almost all cancer patients are desperate for. Often times these treatments offer a Band-Aid solution, requiring new application and never at a discounted price.
Further, increased awareness to the alternative treatments of cancer is moving through the world at an incredible rate. Gone are the days when the only option for any hope to battling cancer was by way of toxic treatments.
As I have said, what BMSN holds, is the wave of the future. A wave that pharma are going to have to pay very close attention to in order to maintain their positions as the big fish they are.
RNA Interference (Min Science) specifically inhibits the enzyme IDO. Tumors can escape the immune system by specifically activating the IDO enzyme. Dr. Min along with his team, clearly demonstrated that by blocking function of IDO, tumors enter remission. But with the recent Benitec licensing, they are going one step further in combating cancer by not only effectively inhibiting the IDO's but also stimulating the immune system to kill the cancer cells.
So, not only are they targeting the cancer cells with environmental friendly fire they are working to teach the body to eliminate the forces that infiltrate and create the environment conducive for cancer cell proliferation.
A double whammy to one of the ugliest plagues life has seen. And a double whammy that you can bet your money that in very short order, BP will be utilizing. And they ain’t getting it for free!
I just increased my GTC to 10.00. :)
LONG BMSN!
True dat, my friend. True dat.
P* 2010-09-23 2010-09-27 19:20:01 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 60,000 $0.04 $2,100.00 1.24002E7 14.29% view
P 2010-09-20 2010-09-27 19:20:01 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 28,000 $0.05 $1,316.00 1.24602E7 -14.89% view
P* 2010-04-12 2010-04-23 15:01:39 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 3,593,270 $0.07 $251,529.00 1.24882E7 -0.00% view
P* 2010-04-12 2010-04-23 15:01:39 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 4,454,990 $0.07 $311,850.00 8,894,940 -0.00% view
P* 2010-04-12 2010-04-16 18:06:39 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 3,593,270 $0.07 $251,529.00 1.24882E7 -0.00% view
P 2010-04-12 2010-04-16 18:06:39 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 4,350,000 $0.10 $429,345.00 8,894,940 -29.08% view
P* 2010-04-12 2010-04-16 18:06:39 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 104,997 $0.07 $7,412.79 4,544,940 -0.85% view
P* 2009-06-22 2009-07-09 19:21:06 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 4,000,000 $0.03 $120,000.00 8,343,150 333.33% view
P* 2009-05-08 2009-05-15 18:47:28 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 226,540 $0.05 $11,327.00 4,569,690 80.00% view
P* 2009-05-08 2009-05-15 18:47:28 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 1,341,500 $0.05 $67,075.00 4,343,150 80.00% view
P 2008-07-07 2008-07-22 18:48:30 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 4,852 $0.00 $0.49 1,676,290 519,900.01% view
P* 2007-07-30 2007-08-03 17:54:38 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond director officer (Cheif Executive Officer) 566,217 $0.25 $141,554.00 1,744,380 60.00% view
P 2007-07-30 2007-08-02 18:39:10 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 100,000 $0.41 $41,000.00 1,178,170 17.07% view
P 2007-06-28 2007-07-02 16:53:02 Bio-Matrix Scientific Group, Inc. BMSN Koos David Raymond CEO 35,000 $0.61 $21,350.00 1,078,170 -16.39% view
P=BUY How many more shares do you want him to buy?